News
December 20, 2016 / News
Vipergen enters into multi-target drug discovery agreement with Merck
Copenhagen, Denmark, December 20, 2016 Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Merck. Under the terms of the agreement, Vipergen’s small molecule discovery engine,…
Read More
June 22, 2016 / News
Vipergen enters into multi-target drug discovery agreement with Daiichi Sankyo
Copenhagen, Denmark, June 22nd,2016–Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Daiichi Sankyo Co., Ltd. (hereinafter “Daiichi Sankyo”). Under the terms of the agreement, Vipergen’ssmall…
Read More
June 19, 2016 / News
Vipergen enters into multi-target drug discovery agreement with Gilead
Copenhagen, Denmark, January 19, 2016 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary secondgeneration DNA-encoded library platform, today announced the initiation of…
Read More
December 21, 2015 / News
Vipergen enters into multi-target collaboration with Europes largest biopharmaceutical company
Copenhagen, Denmark, December 21, 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2 nd generation DNA-encoded library platform, today announced the…
Read More
December 18, 2015 / News
Vipergen enters into multi-target drug discovery agreement with Amgen
Copenhagen, Denmark, December 18 2015 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the signing…
Read More